# Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

> **NCT00906061** · PHASE2 · UNKNOWN · sponsor: **Hospital Arnau de Vilanova** · enrollment: 76 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Gemcitabine and Docetaxel

## Key facts

- **NCT ID:** NCT00906061
- **Lead sponsor:** Hospital Arnau de Vilanova
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2009-10
- **Final completion:** 2011-10
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2009-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00906061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00906061, "Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00906061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*